Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Condition:   Mantle Cell Lymphoma Intervention:   Sponsor:   Samsung Medical Center Active, not recruiting

Source: ClinicalTrials.gov - August 20, 2019 Category: Research Source Type: clinical trials